← Human Trials & Peer-Reviewed Studies

Correlations of insulin resistance and HbA1c with cytokines IGF-1, bFGF and IL-6 in the aqueous humor of patients with diabetic cataract

Plain-language guide to PMID 30657541 (2019): observational study of IGF-1 LR3 in 59 patients, insulin resistance, prediabetes & type 2 diabetes.

Key Facts

PMID
30657541
Journal
European review for medical and pharmacological sciences
Year
2019
Study type
Observational Study
Authors
Zhu HC et al. (3 authors)
DOI
10.26355/eurrev_201901_16742

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of IGF-1 LR3 in the context of insulin resistance, prediabetes & type 2 diabetes, published as an observational study.

The study aimed to investigate the correlations of insulin resistance and hemoglobin A1c (HbA1c) with cytokines [insulin-like growth factor 1 (IGF-1), basic fibroblast growth factor (bFGF) and interleukin-6 (IL-6)] in the aqueous humor of patients with diabetic cataract.

Who Took Part

The study group was 59 patients.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

59 patients with diabetic cataract and 58 patients with simple cataract treated in Jining No. 1 People´s Hospital (Jining, China) from January 2017 to February 2018, were selected randomly.

The levels of homeostasis model assessment of insulin resistance (HOMA-IR) and HbAlc, as well as IGF-1, bFGF and IL-6 in the aqueous humor were compared between the two groups.

How the Study Was Run

The correlations of HOMA-IR and HbAlc with IGF-1, bFGF and IL-6 were analyzed.

What Was Measured

Topics PubMed links to this paper include Aqueous Humor, Biomarkers, Case-Control Studies, Cataract, Diabetes Complications, Fibroblast Growth Factor 2 and Glycated Hemoglobin.

What This Means in Plain Language

This is an observational study of IGF-1 LR3 in 59 patients in people with insulin resistance, prediabetes & type 2 diabetes.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (European review for medical and pharmacological sciences), a journal based in United States.

More context: the IGF-1 LR3 compound page, Insulin resistance, prediabetes & type 2 diabetes research.

Our Notes on the Compound

IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.